产品分类
Product Category详细介绍
| 品牌 | absin | CAS | 873697-71-3 |
|---|---|---|---|
| 分子式 | C20H24FN5O3 | 纯度 | >98% |
| 分子量 | 401.43 | 货号 | abs810613 |
| 规格 | 5mg | 供货周期 | 现货 |
| 主要用途 | is a specific cardiac myosinactivator | 应用领域 | 化工,生物产业,农林牧渔,制药/生物制药,综合 |
Omecamtiv mecarbil (CK-1827452) 873697-71-3
| 产品描述 | |
| 描述 | Omecamtivmecarbil (CK-1827452) is a specific cardiac myosinactivator and a clinical drug for left ventricular systolic heart failure. |
| 纯度 | >98% |
| 储存/保存方法 | Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 别名 | CK-1827452, CK1827452,CK 1827452 |
| 外观 | Powder |
| 可溶性/溶解性 | DMSO 80 mg/mL (199.28 mM) Ethanol 6 mg/mL (14.94 mM) |
| 生物活性 | |
| 靶点 | Myosin ATPase |
| In vitro(体外研究) | In vitro, Omecamtiv mecarbil selectively activates cardiac myosin by increasing the myosin ATPase rate. In isolated cardiac myocytes, Omecamtiv mecarbil results in increase of myocyte contractility and overcomes of the myosin inhibitor BDM without increasing the calcium transient or inhibiting the PDE pathway. |
| In vivo(体内研究) | Omecamtiv mecarbil significantly increases fractional shortening starting at 0.4 mM plasma concentrations in SD rats, sham animals and in rats with heart failure. In conscious dogs with myocardial infarction (MI-sHF), Omecamtiv mecarbil leads to a significant increase in wall thickening (25%), stroke volume (44%), cardiac output (22%) and left ventricular (LV) systolic ejection time (26%). In addition, Omecamtiv mecarbil also results in the decreases of some hemodynamic parameters including heart rate, mean left atrial pressure, and LV end-diastolic pressure. In conscious dogs with left ventricular hypertrophy (LVH-sHF), Omecamtiv mecarbil leads to similar and not statistically different effects on hemodynamic parameters. |
| 研究领域 | |
| 研究领域 | Signal TransductionCytoskeleton / ECMCytoskeletonMotor ProteinsMyosin Drug DiscoverySmall Molecule DrugLead Compound Discovery |
产品咨询